- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/555 - Interférons [IFN]
Détention brevets de la classe C07K 14/555
Brevets de cette classe: 297
Historique des publications depuis 10 ans
|
12
|
22
|
21
|
22
|
27
|
18
|
21
|
25
|
26
|
8
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Opko Biologics Ltd. | 78 |
13 |
| The Regents of the University of California | 19943 |
9 |
| Evotec International GmbH | 80 |
8 |
| Sanofi | 4068 |
8 |
| Superlab Far East Limited | 15 |
7 |
| Werewolf Therapeutics, Inc. | 54 |
7 |
| Regeneron Pharmaceuticals, Inc. | 4261 |
6 |
| Rutgers, The State University of New Jersey | 1893 |
6 |
| Orionis Biosciences Inc. | 96 |
6 |
| Toray Industries, Inc. | 6951 |
5 |
| The Industry & Academic Cooperation in Chungnam National University (IAC) | 458 |
5 |
| Novagen Holding Corporation | 25 |
5 |
| CytomX Therapeutics, Inc. | 222 |
4 |
| Universiteit Gent | 1331 |
4 |
| Vib VZW | 876 |
4 |
| Akseera Pharma Corp. | 12 |
4 |
| The Board of Trustees of the Leland Stanford Junior University | 6424 |
3 |
| Memed Diagnostics Ltd. | 75 |
3 |
| PharmaEssentia Corp. | 50 |
3 |
| Prosit Sole Biotechnology (Beijing) Co. Ltd | 6 |
3 |
| Autres propriétaires | 184 |